Cyteir Therapeutics to Participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference

Rhea-AI Summary

Cyteir Therapeutics, Inc. (NASDAQ: CYT) announced that its CEO, Markus Renschler, MD, will participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference on August 9, 2022, at 12:00 PM EDT. The panel, titled 'Synthetic Lethal (Weapon) – Part 1,' will be accessible via a live webcast from Cyteir's website, with a replay available for 30 days after the event. Cyteir focuses on developing next-generation synthetically lethal therapies for cancer, including its investigational drug CYT-0851, which is in Phase 1/2 trials for various malignancies.

LEXINGTON, Mass.--(BUSINESS WIRE)-- Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced that its President and Chief Executive Officer, Markus Renschler, MD, will participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference on August 9, 2022.

2022 Wedbush PacGrow Healthcare Conference
Date: Tuesday, August 9
Time: 12:00 PM EDT
Panel: Synthetic Lethal (Weapon) – Part 1

A live webcast of the Wedbush panel discussion will be available in the Investors & Media section of the Cyteir website at www.cyteir.com. A webcast replay will also be available on the website shortly after conclusion of the event for 30 days.

About Cyteir Therapeutics, Inc.

Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. At Cyteir, we employ an integrated target discovery approach that incorporates a critical evaluation of the target biology with internal and external information from a variety of genetic and chemical synthetic lethality screens to fuel our drug discovery and development pipeline. Cyteir’s wholly owned lead compound, CYT-0851, is a selective oral investigational drug currently in a Phase 1/2 clinical trial for hematologic malignancies and solid tumors. Follow Cyteir on social media: LinkedIn and Twitter and at www.cyteir.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220801005239/en/

INVESTORS:

Lisa Hayes

Vice President, Investor Relations and Corporate Communications

908-868-8926

Lisa.Hayes@cyteir.com

MEDIA:

Michele Parisi

925-429-1850

mparisi@forwardhealthinc.com

Source: Cyteir Therapeutics

FAQ

What event will Cyteir Therapeutics participate in on August 9, 2022?

Cyteir Therapeutics will participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference on August 9, 2022.

What time will Cyteir's panel discussion start on August 9, 2022?

The panel discussion will start at 12:00 PM EDT.

Where can I watch the Cyteir Therapeutics panel discussion?

The panel discussion can be watched live on Cyteir's website, with a replay available for 30 days after the event.

What is the focus of Cyteir Therapeutics?

Cyteir Therapeutics focuses on the discovery and development of next-generation synthetically lethal therapies for cancer.

What is the status of Cyteir's lead compound, CYT-0851?

CYT-0851 is a selective oral investigational drug currently in a Phase 1/2 clinical trial for hematologic malignancies and solid tumors.